↑Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID21948594.edit
↑Pfeiffer, Francis R.; Wilson, James W.; Weinstock, Joseph; Kuo, George Y.; Chambers, Pamela A.; Holden, Kenneth G.; Hahn, Richard A.; Wardell, Joseph R., Jr.; Alfonso, J. Tobia; et al. (1982). „Dopaminergic activity of substituted 6-chloro-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines”. Journal of Medicinal Chemistry25 (4): 352–358. DOI:10.1021/jm00346a005. PMID7069713.
↑Self DW, Stein L (June 1992). „The D1 agonists SKF 82958 and SKF 77434 are self-administered by rats”. Brain Research582 (2): 349–52. DOI:10.1016/0006-8993(92)90155-3. PMID1356585.
↑Kalivas PW, Duffy P (July 1995). „D1 receptors modulate glutamate transmission in the ventral tegmental area”. Journal of Neuroscience15 (7 Pt 2): 5379–88. PMID7623160.
↑Weed MR, Woolverton WL (December 1995). „The reinforcing effects of dopamine D1 receptor agonists in rhesus monkeys”. The Journal of Pharmacology and Experimental Therapeutics275 (3): 1367–74. PMID8531104.
↑Weed MR, Paul IA, Dwoskin LP, Moore SE, Woolverton WL (October 1997). „The relationship between reinforcing effects and in vitro effects of D1 agonists in monkeys”. The Journal of Pharmacology and Experimental Therapeutics283 (1): 29–38. PMID9336305.
↑Abrahams BS, Rutherford JD, Mallet PE, Beninger RJ (February 1998). „Place conditioning with the dopamine D1-like receptor agonist SKF 82958 but not SKF 81297 or SKF 77434”. European Journal of Pharmacology343 (2-3): 111–8. DOI:10.1016/S0014-2999(97)01531-8. PMID9570457.
↑Tidey JW, Bergman J (June 1998). „Drug discrimination in methamphetamine-trained monkeys: agonist and antagonist effects of dopaminergic drugs”. The Journal of Pharmacology and Experimental Therapeutics285 (3): 1163–74. PMID9618419.